Pertuzumab (anti-HER2)

製品コード：A2008         Batch: A200805

印刷

Pertuzumab, a humanized monoclonal antibody and the first in the class of agents called the HER2 dimerization inhibitors, impairs the ability of HER2 to bind to other members of the HER family, MW: 148 KD.

製品説明

CAS No. 380610-27-5
Formulation 100 mM Pro-Ac, 20mM Arg, pH5.0
Isotype Human IgG1
Source CHO cells
Storage
(From the date of receipt)		 Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles
Shipping Shipped under low temperature conditions
Purity 99%
Protein concentration 11.83mg/ml
Endotoxin Level ＜1EU/mg

カスタマーフィードバック

A2008-Pertuzumab-(anti-HER2).gif

Selleckの高級品が、幾つかの出版された研究調査結果（以下を含む）で使われた：

XMT-2056, a HER2-Directed STING Agonist Antibody-Drug Conjugate, Induces Innate Anti-Tumor Immune Responses by Acting on Cancer Cells and Tumor-Resident Immune Cells [ Clin Cancer Res, 2025, 10.1158/1078-0432.CCR-24-2449] PubMed: 40029253
Development of Fully Human Antibodies Targeting SIRPα and PLA2G7 for Cancer Therapy [ Antibodies (Basel), 2025, 14(1)21] PubMed: 40136470
Characterization of ex vivo expanded natural killer cells for cancer immunotherapy [ Immunol Cell Biol, 2025, 10.1111/imcb.70038] PubMed: 40533418
Intracellular cartilage oligomeric matrix protein augments breast cancer resistance to chemotherapy [ Cell Death Dis, 2024, 15(7):480] PubMed: 38965233
Trastuzumab Potentiates Antitumor Activity of Thiopyrano[2,3-d]Thiazole Derivative in AGS Gastric Cancer Cells [ Molecules, 2024, 29(21)5117] PubMed: 39519758
Enhancing antitumor activity of herceptin in HER2-positive breast cancer cells: a novel DNMT-1 inhibitor approach [ Discov Oncol, 2024, 15(1):640] PubMed: 39527385
Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells [ Int J Mol Sci, 2023, 24(7)6791] PubMed: 37047765
Multi-Targeting Anticancer Activity of a New 4-Thiazolidinone Derivative with Anti-HER2 Antibodies in Human AGS Gastric Cancer Cells [ Int J Mol Sci, 2023, 24(7)6791] PubMed: 37047765
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer [ Front Oncol, 2023, 13:1108242] PubMed: 37469415
The effect of the alpha-specific PI3K inhibitor alpelisib combined with anti-HER2 therapy in HER2+/PIK3CA mutant breast cancer [ Front Oncol, 2023, 13:1108242] PubMed: 37469415

人間や獣医の診断であるか治療的な使用のためにでない。